Almirall (LBTSF) News Today $9.17 0.00 (0.00%) As of 01/29/2025 Add Compare Share Share Headlines Stock AnalysisChartHeadlinesShort Interest All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Almirall at the JPMorgan Conference - Entering a New Era of Sustained GrowthJanuary 14, 2025 | finance.yahoo.comRBC Capital Reaffirms Their Buy Rating on Almirall (0O9B)December 13, 2024 | markets.businessinsider.comAlmirall Launches The Hive, Creating a Novel Collaborative Innovation Hub to Advance Life Sciences and HealthcareDecember 4, 2024 | finance.yahoo.comAlmirall, S.A. (LBTSF) Q3 2024 Earnings Call TranscriptNovember 11, 2024 | seekingalpha.comAlmirall to Present 9-Month 2024 Financial ResultsNovember 11, 2024 | markets.businessinsider.comAlmirall completes EU regulatory procedure for antifungal JubliaOctober 15, 2024 | finance.yahoo.comAlmirall Announces Completion of Decentralized Regulatory Approval Procedure for Efinaconazole in EuropeOctober 15, 2024 | finance.yahoo.comAlmirall (0O9B) Gets a Buy from Kepler CapitalSeptember 29, 2024 | markets.businessinsider.comAlmirall to Present New Data on Biologics for Psoriasis and Atopic Dermatitis and Celebrates 80 Years of Innovation at the EADV CongressSeptember 23, 2024 | finance.yahoo.comLBTSF Almirall, S.A.September 11, 2024 | seekingalpha.comAlmirall, S.A. (LBTSF)August 15, 2024 | finance.yahoo.comAlmirall Shares Rise After Confirmed Targets, Revenue IncreaseMay 13, 2024 | marketwatch.comAlmirall, S.A. reports FY resultsFebruary 20, 2024 | msn.comAlmirall continues its progress to leadership in Medical Dermatology driven by strong growth in the European Dermatology businessFebruary 19, 2024 | finance.yahoo.comAlmirall and Microsoft partner on AI-powered drug discovery in dermatologyFebruary 5, 2024 | msn.comAlmirall, Etherna Team Up to Develop MRNA-Based Dermatology TherapiesDecember 12, 2023 | marketwatch.comAlmirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical DermatologyDecember 12, 2023 | finance.yahoo.comAlmirall Shares Rise on European Approval for Skin DrugNovember 17, 2023 | marketwatch.comAlmirall Receives European Commission Approval of EBGLYSS® (lebrikizumab) for Moderate-to-Severe Atopic DermatitisNovember 17, 2023 | finance.yahoo.comAlmirall and Absci partner on AI-driven dermatological drug developmentNovember 15, 2023 | msn.comAbsci Corporation: Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseasesNovember 14, 2023 | finanznachrichten.deAlmirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseasesNovember 14, 2023 | finance.yahoo.comAbsci, Almirall partner on dermatologic drug developmentNovember 14, 2023 | msn.comAlmirall, S.A. reports 9M resultsNovember 9, 2023 | msn.comAlmirall’s Nine-month 2023 Results:November 9, 2023 | businesswire.comAlmirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for CyclosporineOctober 13, 2023 | businesswire.comAlmirall and EpimAb partner to develop bispecific antibody therapiesOctober 12, 2023 | msn.comEpimAb Biotherapeutics and Almirall Announce Bispecific Antibody License AgreementOctober 12, 2023 | businesswire.comAlmirall's Ilumetri® (tildrakizumab) Significantly Improves Wellbeing for Patients1 and Their Relatives2 in Moderate-to-Severe Plaque PsoriasisOctober 11, 2023 | finance.yahoo.comCentrient Pharmaceuticals joins Almirall’s growing innovation hub in BarcelonaOctober 10, 2023 | businesswire.comEMA’s CHMP supports Almirall’s Ebyglyss for atopic dermatitisSeptember 18, 2023 | msn.comAlmirall, S.A. reports 1H resultsJuly 24, 2023 | msn.comAlmirall: Ilumetri® (tildrakizumab) significantly improved the wellbeing of patients with moderate-to-severe plaque psoriasisJuly 7, 2023 | finance.yahoo.comAlmirall announces the pricing and closing of its €200mm non pre-emptive share capital increaseJune 13, 2023 | finance.yahoo.comAlmirall's Q1 core earnings beat estimates on Europe dermatology operationsMay 8, 2023 | news.yahoo.comAlmirall's core earnings beat estimates in Q1May 8, 2023 | reuters.comAlmirall’s First Quarter 2023 ResultsMay 8, 2023 | finance.yahoo.comAlmirall: Up to 73% of Atopic Dermatitis Patients Taking Lebrikizumab Had Improved or Cleared Skin on Face or Hands in New AnalysisMay 1, 2023 | finance.yahoo.comCREDIT SUISSE - EUROPE Maintains Almirall (XMAD:ALM) Neutral RecommendationApril 21, 2023 | msn.comAlmirall, S.A. (ALM.MC)April 13, 2023 | finance.yahoo.comAlmirall, The First to Assess Wellbeing in a Dermatology Clinical StudyApril 12, 2023 | finance.yahoo.comAlmirall Shares Rise on Swing to 2022 Net Profit, CEO ConfirmationFebruary 20, 2023 | marketwatch.comSpain's Almirall expects core earnings to fall in 2023February 20, 2023 | reuters.comAlmirall to Participate in the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 4, 2023 | nz.finance.yahoo.comSpain's Almirall Q3 core earnings fall 13%; keeps outlookNovember 10, 2022 | msn.comWeek In Review: YishengBio To List On Nasdaq Via SPAC Merger At An $834 Million ValueOctober 3, 2022 | seekingalpha.comSimcere and Almirall Enter into a Licensing Agreement for IL-2 mu-FcSeptember 29, 2022 | benzinga.comAlmirall's Klisyri® (tirbanibulin) receives strong recommendation in American Academy of Dermatology AK guideline updateAugust 18, 2022 | finance.yahoo.comAlmirall, S.A. 2022 Q2 - Results - Earnings Call PresentationJuly 26, 2022 | seekingalpha.comAlmirall, S.A. (LBTSF) CEO Gianfranco Nazzi on Q2 2022 Results - Earnings Call TranscriptJuly 25, 2022 | seekingalpha.com Get Almirall News Delivered to You Automatically Sign up to receive the latest news and ratings for LBTSF and its competitors with MarketBeat's FREE daily newsletter. Email Address LBTSF Media Mentions By Week LBTSF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LBTSF News Sentiment▼0.000.76▲Average Medical News Sentiment LBTSF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LBTSF Articles This Week▼10▲LBTSF Articles Average Week Get Almirall News Delivered to You Automatically Sign up to receive the latest news and ratings for LBTSF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TGIFF News FFNTF News ABSCF News ACRHF News AZFL News ERBB News AVTBF News AVCNF News BIOYF News BOIRF News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:LBTSF) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementThe #1 Coin Poised to Soar Under Trump Pro-Crypto White House could make this the investment opportunity of...Crypto 101 Media | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredElon’s ultimate power move?THE ELON SHOCK All of Elon Musk’s strange behavior may soon make sense… and impact the markets in a way no ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Almirall, S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Almirall With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LBTSF Stock Alerts